Rheumatoid arthritis
RA is a chronic inflammatory disease resulting in severe morbidity and premature mortality. This review explores in a series of two articles, the current developments in the pathogenesis, diagnosis, monitoring and management of patients with RA. The diagnosis of early as well as established disease is discussed, including the diagnostic criteria. Particular emphasis is placed on the pitfalls and benefits of early diagnosis and early intervention. Prevention and limitation of comorbidity from the disease is highly important. This can be achieved following a paradigm shift in RA management. The emphasis is now on early introduction of disease-modifying anti-rheumatic drugs, including timely use of highly efficacious pharmacological innovations. Side effects, including peri-operative implications of pharmacological therapy, are discussed. Current therapeutic strategy to manage this disease should also be applied in resource-poor settings and developing countries. These therapies are cost effective if used early and judiciously, giving hope to many patients with RA.
| Main Authors: | , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Medpharm Publications
2010
|
| Online Access: | http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S1681-150X2010000100003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | RA is a chronic inflammatory disease resulting in severe morbidity and premature mortality. This review explores in a series of two articles, the current developments in the pathogenesis, diagnosis, monitoring and management of patients with RA. The diagnosis of early as well as established disease is discussed, including the diagnostic criteria. Particular emphasis is placed on the pitfalls and benefits of early diagnosis and early intervention. Prevention and limitation of comorbidity from the disease is highly important. This can be achieved following a paradigm shift in RA management. The emphasis is now on early introduction of disease-modifying anti-rheumatic drugs, including timely use of highly efficacious pharmacological innovations. Side effects, including peri-operative implications of pharmacological therapy, are discussed. Current therapeutic strategy to manage this disease should also be applied in resource-poor settings and developing countries. These therapies are cost effective if used early and judiciously, giving hope to many patients with RA. |
|---|